Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMALIZUMAB Cause Blood immunoglobulin e increased? 692 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 692 reports of Blood immunoglobulin e increased have been filed in association with OMALIZUMAB (Omalizumab-igec). This represents 1.1% of all adverse event reports for OMALIZUMAB.

692
Reports of Blood immunoglobulin e increased with OMALIZUMAB
1.1%
of all OMALIZUMAB reports
8
Deaths
232
Hospitalizations

How Dangerous Is Blood immunoglobulin e increased From OMALIZUMAB?

Of the 692 reports, 8 (1.2%) resulted in death, 232 (33.5%) required hospitalization, and 55 (7.9%) were considered life-threatening.

Is Blood immunoglobulin e increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMALIZUMAB. However, 692 reports have been filed with the FAERS database.

What Other Side Effects Does OMALIZUMAB Cause?

No adverse event (9,736) Asthma (9,354) Urticaria (9,231) Off label use (9,199) Dyspnoea (8,323) Drug ineffective (6,747) Cough (5,926) Pruritus (5,224) Fatigue (5,053) Malaise (4,820)

What Other Drugs Cause Blood immunoglobulin e increased?

ALBUTEROL (469) MONTELUKAST (340) PREDNISONE (297) BUDESONIDE\FORMOTEROL (293) TIOTROPIUM (290) MEPOLIZUMAB (246) BUDESONIDE (198) CICLESONIDE (163) FLUTICASONE\SALMETEROL (144) IPRATROPIUM (119)

Which OMALIZUMAB Alternatives Have Lower Blood immunoglobulin e increased Risk?

OMALIZUMAB vs OMAVELOXOLONE OMALIZUMAB vs OMBITASVIR OMALIZUMAB vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMALIZUMAB vs OMEGA-3-ACID ETHYL ESTERS OMALIZUMAB vs OMEGA-3-CARBOXYLIC ACIDS

Related Pages

OMALIZUMAB Full Profile All Blood immunoglobulin e increased Reports All Drugs Causing Blood immunoglobulin e increased OMALIZUMAB Demographics